linjc16/ctgov huggingface dataset:
Development of Machine Learning Models for the Prediction of BMI and Complications After Bariatric Surgery (CABS-Study)

Study Overview
=================
Brief Summary
-----------------
This Study aims to develop machine learning models with the ability to predict patients' BMI and complications after Bariatric Surgery (CABS-Score). This Study also aims to develop machine learning models with the ability to predict diabetic (DM II)patients' remission rate after Bariatric Surgery. The service mentioned above will be publicly available as a web-based application

Official Title
-----------------
Development of Machine Learning Models for the Prediction of BMI and Complications After Bariatric Surgery (CABS-Study)

Conditions
-----------------
Body Weight, Post-Op Complication, Anastomosis, Leaking, Hiatal Hernia, GERD, Internal Hernia, Mesenteric Hernia, Intussusception, Diabetes Mellitus, Type 2, Sleep Apnea, Obstructive

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing bariatric surgery Patients >18 years Exclusion Criteria: Patients <18 years Patients who cannot be followed up on for more than 6 month after surgery Patients who are unable to provide informed approval to participate according to each centre's rules will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complication after surgery |  | [Time Frame: From index surgery up to 3 months postoperatively] | 
| Body mass Index (KG/m2) after surgery |  | [Time Frame: From index surgery up to 1 year postoperatively] | 
| Diabetes mellitus type II remission rate postoperatively |  | [Time Frame: From index surgery up to 2 year postoperatively] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bariatric Surgery, Machine learning, Clinical prediction modelling, Artificial intelligence
THE EXPERIENCES OF PROFESSIONALS WITH REFUGEE PATIENTS

Study Overview
=================
Brief Summary
-----------------
This study was conducted to examine the experiences and feelings of health professionals while providing care to refugee children and families in pediatric emergency service.

Official Title
-----------------
A QUALITATIVE RESEARCH ON THE EXPERIENCES OF PEDIATRIC EMERGENCY SERVICE PROFESSIONALS WITH REFUGEE PATIENTS

Conditions
-----------------
Emergencies, Health Personnel Attitude, Child Development, Qualitative

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health professionals who worked in the pediatric emergency department for at least 1 year were included. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| This qualitative research data were collected by semi-structured interview form | In order to collect data, the researchers prepared four open-ended, basic questions: (1) What are your feelings about the refugees who migrated to our country? Can you explain? (2) Can you explain the feelings and experiences with refugee patients in pediatric emergency service? (3) How did working with refugee patients affect your thoughts about your profession? (4) What kind of problems did you experience while providing care to refugee patients in pediatric emergency services? | 1 month |
Effect of Action Observation Physical Training on Quality of Upper Limb and Functional Independence in Children With Hemiplegia

Study Overview
=================
Brief Summary
-----------------
30 children with a diagnosis of hemiplegic cerebral palsy

Detailed Description
-----------------
children aged 6-9 years were randomized into 2 groups, control group and study group

Official Title
-----------------
Effect of Action Observation Physical Training on Quality of Upper Limb and Functional Independence in Children With Hemiplegia

Conditions
-----------------
Hemiplegic Cerebral Palsy

Intervention / Treatment
-----------------
* Other: action observation physical training
* Other: Traditional physical therapy training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: manual ability classification system level II or III, Modified ashwarth scale 1+ or 2 Exclusion Criteria: visual or auditory problems ,fixed deformities

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Action observation arm<br> | Other: action observation physical training<br>* Action observation training 3 sessions per week for 3 successive months<br>|
| Active Comparator: traditional physical training<br> | Other: Traditional physical therapy training<br>* Traditional physical therapy training 3 sessions per week for 3 successive months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Upper Extremity skills test | reliable and valid scale,evaluate quality of upper extremity function in four domains dissociated movement,grasp,weight bearing and protective extension | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HCP
Influence of Vasopressors on Anti-Xa Activity in Critically Ill Patients

Study Overview
=================
Brief Summary
-----------------
Critically ill patients require antithrombotic prophylaxis. At the same time, majority of them is receiving various vasopressors. The aim of the study is to determine whether there is a difference in anti-Xa activity, which is a marker of anti thrombotic activity of low molecular weight heparins, between the patients receiving norepinephrine with argipressin, compared to those receiving norepinephrine alone.

Official Title
-----------------
Anti-Xa Activity in Patients Receiving Different Vasopressors.

Conditions
-----------------
Critical Illness, Thrombosis

Intervention / Treatment
-----------------
* Diagnostic Test: Serum anti-Xa activity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Circulatory failure Supported by continuous infusion of noradrenaline or noradrenaline and argipressin Receiving subcutaneous dalteparin for the prevention of venous thromboembolism. Exclusion Criteria: Contraindications for dalteparin Severe coagulopathy Acute or subacute bacterial endocarditis Pregnant women BMI (body mass index) > 30kg/m2 Chronic kidney disease with eGFR (estimated glomerular filtration rate) < 30 ml/min/1.73 m2 Renal replacement therapy The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NOR+ARG<br>Critically ill patients receiving norepinephrine and argipressin, with antithrombotic prophylaxis with 5000 IU of dalteparin. | Diagnostic Test: Serum anti-Xa activity<br>* 4 hours after third dose of dalteparin, serum anti-Xa activity is measured<br>|
| NOR<br>Critically ill patients receiving norepinephrine alone, with antithrombotic prophylaxis with 5000 IU of dalteparin. | Diagnostic Test: Serum anti-Xa activity<br>* 4 hours after third dose of dalteparin, serum anti-Xa activity is measured<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti-Xa activity | IU anty-Xa/ml | 4 hours after third dose |
Indicators of Anastomotic Leak After Colorectal Surgery

Study Overview
=================
Brief Summary
-----------------
We reviewed the patient underwent colorectal surgery with anastomosis and identified patients with anastomotic leak. Then we started to figure out what blood investigation could be related to anastomotic leak.

Official Title
-----------------
Blood Indices as Predictors of Anastomotic Leak After Colorectal Surgery - Is It Useful? A Retrospective Analysis.

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient underwent colorectal surgery with anastomosis Exclusion Criteria: Patient has no colon or rectum as part of anastomosis Patient with more than one procedure within 6 month

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of blood investigations in detecting anastomotic leak |  | JAN 2015 - DEC 2022 |
SOFA and APACHE II Scoring Systems for Predicting Outcome of Neurological Patients Admitted in a Tertiary Hospital Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to compare the discriminative power of commonly used scoring systems, namely the sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation II (APACHE II) in the intensive care unit of a tertiary care hospital.

Detailed Description
-----------------
This was a retrospective cross-sectional study including patients admitted to the ICU of TU Teaching Hospital with a neurological diagnosis from January 1, 2022, to December 31, 2022. This study uses data collected prospectively as part of the Nepal Intensive Care Research Foundation (NICRF) dataset. The ICU database contained information for all components of the APACHE II and SOFA score with physiological data collected for the length of ICU, and hospital stay. Both SOFA and APACHE II were calculated from the admission data or if not available from the earliest data recorded after admission in ICUs.

Official Title
-----------------
SOFA and APACHE II Scoring Systems for Predicting Outcome of Neurological Patients Admitted in a Tertiary Hospital Intensive Care Unit

Conditions
-----------------
Neurologic Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted with neurological diagnosis in ICUs Exclusion Criteria: Patients with missing data Patients with ICU length of stay < 24 h
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | The outcome measure was ICU mortality (survivor vs non-survivor) | 1 year |
Comparison of the Epifaith® Syringe With the Plastic Syringe

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to compare the efficiency of identifying epidural space with either the Epifaith® syringe or the plastic syringe in parturients. The main questions it aims to answer are: Whether it consume less time identifying epidural space with the Epifaith® syringe Whether the usage of the Epifaith® syringe decrease the complication rate and failure of labor analgesia Participants will receive labor analgesia either with the Epifaith® syringe or the plastic syringe conducted by experienced resident doctors.

Official Title
-----------------
Compare the Epifaith® Syringe With the Plastic Syringe for Identification of the Epidural Space in Parturients: A Prospective Randomized Control Study

Conditions
-----------------
Epidural; Anesthesia, Headache, Analgesia

Intervention / Treatment
-----------------
* Procedure: Labor analgesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA II to III Require labor analgesia Has submitted inform consent Exclusion Criteria: ASA IV or above Coagulopathy Spinal deformity Neurological, psychological, cardiopulmonary disorder Active liver or kidney injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: The Epifaith® syringe<br> | Procedure: Labor analgesia<br>* Perform epidrual analgesia for parturients between 18 to 45 year-old<br>|
| Active Comparator: The plastic syringe<br> | Procedure: Labor analgesia<br>* Perform epidrual analgesia for parturients between 18 to 45 year-old<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time consumed to identify the epidural space | Starting on the moment which the syringe be attached to the needle | During the procedure |
ASA 81 mg vs 162 mg During Frozen Embryo Transfer (FET)

Study Overview
=================
Brief Summary
-----------------
The use of low dose aspirin is recommended for high risk patients to reduce the risk of pre-eclampsia, placental abruption and antepartum hemorrhage. Recent studies have shown that in a specific population, the use of low dose aspirin might reduce the risk of preterm birth in pregnant women with singleton pregnancy. In June 2022, clinique ovo started implementing the use of Aspirin 162 mg instead of 81 mg in the frozen embryo transfer cycles based on recent study outcomes. The use of Aspirin 162 mg might have additional benefits on the embryo transfer outcomes by decreasing the miscarriage. Moreover this can be continued until late in pregnancy without adverse effects.

Official Title
-----------------
Retrospective Study to Assess if Aspirin 162 mg is Better Than 81 mg for Embryo Transfer Outcomes

Conditions
-----------------
Fertility Disorders

Intervention / Treatment
-----------------
* Other: Frozen embryo transfer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women taking aspirin 81 mg or 162 mg prior to an autologous embryo transfer Age < 40 years old Embryo transfer cycle done at clinique ovo Exclusion Criteria: Egg or embryo recipient History of recurrent miscarriages, defined as ≥ 3 consecutive losses Patients that needed Viagra, PRP or other modalities to improve their endometrial thickness Uterine factor infertility Abnormal hormonal profiles Stimulated embryo transfer cycles History of recurrent implantation failure defined as failed ≥ 2 euploid embryos transfer or ≥ 3 blastocysts

Ages Eligible for Study
-----------------
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Aspirin 81 mg for Frozen Embryo Transfer (FET)<br>Subjects were prescribed Aspirin 81 mg to be started on the third day of their menstrual cycle in preparation for their FET. | Other: Frozen embryo transfer<br>* A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy<br>|
| Aspirin 162 mg for Frozen Embryo Transfer (FET)<br>Subjects were prescribed Aspirin 162 mg to be started on the third day of their menstrual cycle in preparation for their FET | Other: Frozen embryo transfer<br>* A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare clinical pregnancy rate between patients prescribed Aspirin 81 mg vs Aspirin 162 mg | clinical pregnancy is the presence of fetal heartbeat at the viability ultrasound | Time Frame: 6 to 8 weeks after Frozen Embryo Transfer |
Caregiver Solutions for Dementia Patients

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to test a mobile application amongst caregiver's supporting patients diagnosed with Alzheimer's Disease and Related Dementias (ADRD). The main question it aims to answer is: Will caregivers supporting patients diagnosed with ADRD utilize a mobile application to routinely report symptoms of the patients they care for?

Official Title
-----------------
Identifying Specifications for Caregiver-assisted Solutions to Assess Dementia Patient Needs at Home

Conditions
-----------------
Alzheimer's Disease, Dementia, Caregivers, Remote Monitoring

Intervention / Treatment
-----------------
* Behavioral: Digital Outpost


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caregiver of a Duke patient with Alzheimer's disease or Alzheimer's disease-related dementias (ADRD), participating in the Duke Dementia Family Support Program The ability to speak and understand English Age > 18 years Exclusion Criteria: Those unable to speak and understand English Age ≤ 18 years
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Digital Outpost<br> | Behavioral: Digital Outpost<br>* A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Days that Participants Use Digital Outpost | Completion of at least 75% of Digital Outpost across 4 days within a 2-week period | Time Frame up to week 2 | 
| Number of Clinical Assessments Completed | Completion of at least 75% of Clinical Assessments | Time Frame up to week 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usability as Measured by the System Usability Scale at 2 weeks | The System Usability Scale will be used for rating technology usability. The measure has 10 items. Each item is measured on a 10-point scale ranging from 0-10. The total score ranges from 0-100, where higher scores indicate greater usability. | Time Frame 2 weeks |
Immunological Indices and Infections Among Pesticide Applicators in Sohag Governorate

Study Overview
=================
Brief Summary
-----------------
The human body gets exposure to pesticides either directly or indirectly. By using pesticides on crops, humans come in direct contact with them and they affect the heaith Immune system is the first defense line against pathogenic organisms; however, it is altered by the vulnerable environmental factors such as pesticides, which can cause structural or functional alterations in humoral or cell mechanisms (nonspecific or adaptive) of the immune response which lead to an increase in the susceptibility to infections

Official Title
-----------------
Immunological Indices and Infections Among Pesticide Applicators in Sohag Governorate

Conditions
-----------------
Pesticide Adverse Reaction

Intervention / Treatment
-----------------
* Diagnostic Test: Blood sample test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pesticide applicators Age ;20-60 years Exposure to pesticides for more than 3 months Exclusion Criteria: Subjects have recent severe trauma or surgery or recent infections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: pesticide applicators<br>This group contain cases | Diagnostic Test: Blood sample test<br>* Blood sample will be taken to determine immunological indices<br>|
| Active Comparator: control<br>control group | Diagnostic Test: Blood sample test<br>* Blood sample will be taken to determine immunological indices<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| immunlogical indices | immunoglobulins (IgG ,IgE) | 12 months |